These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35658835)

  • 1. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon.
    Abongwa LE; Nyamache AK; Charles F; Torimiro J; Emmanuel N; Domkam I; Eyongetah M; Jude B; Mua FH; Bella S; Tamboh TC; Moungang EC; Ngum V; Okemo P
    BMC Gastroenterol; 2022 Jun; 22(1):286. PubMed ID: 35658835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou.
    Wang Y; Yang Z; Li J; Wu Z; Liu X; Wang H; Chen Y; Wang Z; Tong Z; Li X; Ren F; Jin M; Mao G
    PLoS One; 2024; 19(9):e0305461. PubMed ID: 39302927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
    Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
    Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
    Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
    Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine
    Sorsa A
    Open Med Inform J; 2018; 12():11-18. PubMed ID: 29875890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon.
    Pangmekeh PJ; Awolu MM; Gustave S; Gladys T; Cumber SN
    Pan Afr Med J; 2019; 33():87. PubMed ID: 31489065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
    Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL
    AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).
    National Toxicology Program
    Natl Toxicol Program Genet Modif Model Rep; 2013 Oct; (16):1-236. PubMed ID: 24503698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database.
    Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Sommet A
    Therapie; 2018; 73(3):257-266. PubMed ID: 29195713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.